Affiliations 

  • 1 School of Pharmacy, International Medical University (IMU), Bukit Jalil, Kuala Lumpur, 57000, Malaysia
  • 2 Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Bukit Jalil, Kuala Lumpur, 57000, Malaysia. Electronic address: Dinesh_Kumar@imu.edu.my
  • 3 Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Bukit Jalil, Kuala Lumpur, 57000, Malaysia
  • 4 Department of Pharmaceutical Technology, School of Pharmacy, International Medical University (IMU), Bukit Jalil, Kuala Lumpur, 57000, Malaysia
  • 5 Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, Uttar Pradesh, 201313, India
  • 6 Department of Pharmaceutical Sciences, Yarmouk University-Faculty of Pharmacy, Irbid, 566, Jordan
  • 7 School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, County Londonderry, Northern Ireland, UK
  • 8 Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001, India
  • 9 School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, 173 212, India
  • 10 Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney (UTS), Ultimo, NSW, 2007, Australia
  • 11 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), Ultimo, NSW, 2007, Australia
  • 12 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur, 302017, India
  • 13 Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, The University of Newcastle (UoN), Callaghan, NSW, 2308, Australia
  • 14 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), Ultimo, NSW, 2007, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia
  • 15 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), Ultimo, NSW, 2007, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia
  • 16 Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, The University of Newcastle (UoN), Callaghan, NSW, 2308, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney (UTS), Ultimo, NSW, 2007, Australia
  • 17 Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, The University of Newcastle (UoN), Callaghan, NSW, 2308, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), Ultimo, NSW, 2007, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia. Electronic address: Kamal.Dua@uts.edu.au
Eur J Pharmacol, 2020 Jul 15;879:173139.
PMID: 32343971 DOI: 10.1016/j.ejphar.2020.173139

Abstract

Chronic airway inflammatory diseases are characterized by persistent proinflammatory responses in the respiratory tract. Although, several treatment strategies are currently available, lifelong therapy is necessary for most of these diseases. In recent years, phytophenols, namely, flavonoids, derived from fruits and vegetables have been gaining tremendous interest and have been extensively studied due to their low toxicological profile. Naringenin is a bioflavonoid abundantly found in citrus fruits. This substance has shown notable therapeutic potential in various diseases due to its promising diverse biological activities. In this review, we have attempted to review the published studies from the available literature, discussing the molecular level mechanisms of naringenin in different experimental models of airway inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis and cystic fibrosis. Current evidences have proposed that the anti-inflammatory properties of naringenin play a major role in ameliorating inflammatory disease states. In addition, naringenin also possesses several other biological properties. Despite the proposed mechanisms suggesting remarkable therapeutic benefits, the clinical use of naringenin is, however, hampered by its low solubility and bioavailability. Furthermore, this review also discusses on the studies that utilise nanocarriers as a drug delivery system to address the issue of poor solubility.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.